News and Views
Nature Medicine 13, 675 - 677 (2007)
doi:10.1038/nm0607-675
HER3 and mutant EGFR meet MET
Carlos L Arteaga1
- Carlos L. Arteaga is in the Departments of Medicine and Cancer Biology and the Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA. e-mail: carlos.arteaga@vanderbilt.edu
Abstract
Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor develop resistance to tyrosine kinase inhibitors by recruiting the MET receptor kinase to activate HER3 and the PI3K-Akt cell survival pathway.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cancer Mixing cocktailsNature News and Views (25 Oct 2007)
HighlightsClinical Pharmacology & Therapeutics News and Views
See all 3 matches for News And ViewsRESEARCH
Dual MET?EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancerBritish Journal of Cancer Original Article
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersOncogene Original Article
See all 9 matches for Research
